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Abstract
Background The participation of inflammation in the
progression of cancer for many years have been the subject
of research.
Methods In the 19th century, there was evidence that an
acute inflammation may inhibit the development of cancer.
However, chronic inflammation affects the progression of
the disease.
Results Today, it is known that inflammation and cancer
use similar mechanisms of development such as severe cell
proliferation or angiogenesis. It has been shown that pro-
longed presence of inflammatory cells and factors in the
tumor microenvironment can accelerate its growth and
inhibit apoptosis of transformed cells.
Conclusion In this article we present a brief history of the
discovery mechanisms and potential links between acute
and chronic inflammation and cancer.
Keywords Acute inflammation  Chronic inflammation 
Cancer  Adhesion molecules
Introduction
In 1863, Rudolf Virchow put forward a hypothesis that
infiltrated immune cells reflect the place where cancer
lesions appear in the inflamed tissue [1]. Not earlier than a
century later, Dvorak showed that carcinogenesis and
inflammatory conditions have common developmental
pathways, such as proliferation, increased cell survival and
migration, and enhanced angiogenesis which are controlled
by growth factors, proinflammatory cytokines and proan-
giogenic factors. Moreover, the author observed that the
cells involved in inflammation also infiltrated cancer tissue
[2, 3] and defined cancer as a ‘‘wound that does not heal’’.
Therefore, we believe that in order to fully elucidate the
role of an inflammatory condition in carcinogenesis, first
we should have a profound understanding of what
inflammation really is.
Short brief history
The discovery and understanding of inflammatory mecha-
nisms dates back to the ancient times of Egyptians and
Greeks. The first description of inflammation appears in the
works of Aulus Cornelius Celsus, who defined four basic
inflammatory signs and symptoms: redness, swelling,
warmth and pain. In 2nd century AD, a Roman surgeon
Galen defined the inflammatory state as a favorable early
component of healing processes in injured tissues, leading
to recovery. Some authors suggest that he introduced the
fifth sign of inflammation, i.e., function loss. However,
according to most scientists, the term functio laesa was
introduced in 1871 by Virchow [4].
Although ancient scientists based their concepts mainly
on observations and intuition and not on profound investi-
gations, they initiated later experiments aimed to discover
the mechanisms involved in the inflammatory process. The
invention of a microscope was a breakthrough in their
understanding, making it possible to observe the microcir-
culatory changes in inflamed tissues [5]. For instance, blood
clotting ‘‘tendency’’ was discovered (Gaubius 1794) and
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angiogenesis was first described as the process of new vessel
formation in healing tissue. In 1824, Dutrochet showed the
ability of leukocytes to migrate within the blood and
15 years later Weyner described the process of leukocyte
rolling on the endothelium. Molecular changes in the vas-
cular walls were found to underlie the adhesion of leuko-
cytes to the endothelium. In nineteenth century, Virchov
propagated research into an inflammatory state [6]. Con-
trary to Galen, he described the inflammatory condition as a
pathological process associated with the excessive inflow
and proliferation of cells caused by the release of nutrients
from damaged blood vessels. He was the first to observe the
cellular nature of an inflammatory response. He also
emphasized the involvement of leukocytes in inflammation,
although he erroneously concluded that these cells were
responsible for infection and tissue damage. A Virchov’s
student, Cohnheim (1867) suggested that the increased
‘‘porosity’’ of blood vessels is associated with fluid escape
to the extravascular space. Using a microscope he was the
first to describe the sequences that occur during an inflam-
matory condition; however, like his master, he wrongly
defined the functions of leukocytes [7]. It was only a Rus-
sian scientist, Miecznikow, who refuted these theories and
proved that it was the invasion of a foreign agent that caused
the migration of host cells to the infected site, phagocytosis
and damage of pathogens. In the subsequent years, the role
of inflammatory cells (including phagocytes) was described,
whereas research conducted by Rocha e Silva showed the
involvement of ‘‘chemical mediators’’ in the development
of an inflammatory condition, which supplemented the
knowledge of an inflammatory response [4].
Currently, we know that irrespective of the triggering
agent, tissue damage activates signals that initiate and
support the immune response of the host, able to eliminate
a damaging agent and to repair tissues [8]. Pathogen
invasion activates inflammatory cells, macrophages and
mast cells that generate and release cytokines (TNF-a, IL-
1b, IL-6) and proinflammatory chemokines (IL-8, MCP-1,
MIP-1a), which together with chemoattractants (bacterial
toxins) stimulate attraction of circulating leukocytes to the
site of inflammation [9].
Inflammatory condition step by step
The initial stage of an inflammatory response involves
leukocyte marginalization. It takes place in small-diameter
vessels, in which inflammatory cells do not migrate to the
center but are pushed towards the vascular walls, where the
process of their endothelial rolling begins. TNF-a, his-
tamine and other mediators of inflammation stimulate
translocation of P-selectin from Weibel–Palade corpuscles,
which is later incorporated in the endothelial cell
membrane. Selectin interacts with sialylated or fucosylated
carbohydrate residues of the Lewis group antigens, which
act as their ligands. PSGL-1 is best known among them
[10]. However, any adequately modified glycoprotein can
be a potential selectin receptor, like CD34, which having
been transformed on the endothelial surface becomes
L-selectin receptor on leukocytes [11]. Ligand binding to
selectin is a dynamic process and the bonds being formed
undergo rapid dissociation. Many times the binding of
leukocytes to endothelium slows down their vascular flow
from 1000 to 30 lm/s. A few hours after activation,
E-selectin appears on the endothelial surface [12]. P-se-
lectin mediates binding at high shear stress, whereas
E-selectin takes part in slow leukocyte rolling (low shear
stress). This is associated with partial leukocyte integrin
activation [13]. The rolling leukocytes may have a direct
contact with endothelium, due to which they may be acti-
vated by inflammatory factors (chemokines) present on the
endothelial surface.
Chemokines are produced by endothelial cells or inter-
stitial inflammatory cells and then transported to the vas-
cular lumen, where they bind to heparin sulfate
glycosaminoglycans on the endothelial surface. Contact of
these proteins with specific leukocyte receptors (a subgroup
of receptors conjugated with G protein) causes the trans-
mission of a signal that activates integrins present on the
inflammatory cells [14].
Integrins belong to a family of heterodimeric adhesion
receptors that remain in the resting inactive conformation.
Most integrins are the extracellular matrix proteins. During
activation changes take place in the arrangement of these
proteins, which allows binding to a ligand [15]. Leukocytes
have on their surface members of the b2 family (CD18),
whose main ligands, i.e., the immunoglobulin-like mole-
cules, ICAM-1 and ICAM-2, are present on the endothe-
lium [16]. The surface of lymphocytes and monocytes
exhibits the b1 family integrins (VLA-4, CD49d/CD29,
a4b1), which bind to VCAM-1 molecules [17]. Following
activation, integrins bind leukocytes tightly to the
endothelial surface, causing their complete arrest. Next,
leukocytes ‘‘crawl’’ to the contact point of endothelial cells
where they prepare for extravasation. The process of
‘‘crawling’’ is mediated by proteins belonging to the
leukocyte and endothelial integrins, i.e., Mac-1 (CD11b/
CD18) that bind ICAM-1. In the case of monocytes, the
transmigration is mediated also by LFA-1 (CD11a/CD18)
and ICAM-2 [18]. During diapedesis leukocytes assume
the amoeboid shape as a result of cytoskeletal alterations
and push their way between endothelial cells [19]. The
stages of rolling, activation, adhesion and ‘‘crawling’’ are
reversible and require heterophilic bonds. On the contrary,
diapedesis is a no-return path, during which leukocytes
interact due to homophilic bonds [20].
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PECAM-1 is the first molecule reported to take part in
transmigration (TEM). It shows a specific distribution on
the cell surface. PECAM-1 on leukocytes has been found
dispersed throughout the cell membrane, whereas on
endothelial cells its highest level has been shown at the cell
contact point. Apart from PECAM-1, such distribution is
also characteristic of CD99 protein [21, 22]. Leukocytes’
migration to the extravascular space is associated with the
fact that they have to pass through the interstitial tissue. It
has been suggested that neutrophils and monocytes migrate
through the basement membrane to the sites with the
lowest expression of collagen IV and laminin 10. This
process is to delimit injuries caused by proteolytic enzymes
used by leukocytes during their passage to the site of
damage. The process occurs when the inflammatory cell
CD11a binds to pericyte-ICAM-1 to allow leukocytes to
reach the sites with the lowest density of the collagen
network [23]. Having reached the site of damage, leuko-
cytes eliminate the pathogen through the activation of
aerobic and anaerobic killing. If the process runs properly,
the elimination of the inflammatory factor suppresses the
inflammation thanks to the action of anti-inflammatory
mediators. For instance, the production of proinflammatory
prostaglandins is decreased and the generation of anti-in-
flammatory lipoxins that attract monocytes, IL-10 or TGF,
is increased [24].
Neutrophils which appear early at the site of damage
constitute the first line of body defense. To a large extent,
they are able to eliminate a pathogen on their own. Other
cells include monocytes and lymphocytes initiating healing
and generation of immunological memory [25].
When the inflammatory cells are not able to eliminate a
pathogen, acute inflammatory condition may turn chronic.
This chronic phase is characterized by hyper-intensive
leukocyte infiltration of injured tissues, which results in the
formation of leukocyte infiltrates. They were first described
by Virchov when he examined tumor tissues. He observed
that the ‘‘lymphoreticular infiltrate reflected the origin of
cancer at sites of chronic inflammation’’ [1]. The elucida-
tion of the mechanisms responsible for the development of
inflammation initiated the research into mutual relationship
to neoplastic disease [26].
Acute inflammatory condition: not always bad
The fact that inflammation can have a double role in the
development of cancer was already observed in the 19th
century (1868) by a German physician Burns. He described
cases of severe streptococcal infection during which
patients experienced regression of neoplastic disease. More
than 20 years later, this fact was taken into consideration
by Coley who created the so called ‘‘Coley’s toxin’’, a
suspension of gram-negative bacterial cells which he suc-
cessfully administered to cancer patients. The pathogen-
induced body stimulation results in the activation of the
immune system, which not only fights the bacteria but also
inhibits tumor growth. The role of TNF-a (tumor necrosis
factor), whose release is stimulated, among others, by a
bacterial toxin, LPS (lipopolysaccharide), has been proved
[27]. Currently, induced acute inflammation is used in the
therapy of squamous cancer of the bladder. Patients receive
a special vaccine against tuberculosis containing an atten-
uated Mycobacterium bovis strain (Mycobacterium bovis
bacillus Calmette–Guerin—BCG) directly to the urinary
bladder [28]. Induced immune reaction is associated with
cytokine secretion, including interleukin-1 (IL-1), IL-2, IL-
5, IL-6, IL-8, IL-10, IL-12, IL-15, IL-18, TNF-a, GM-CSF
and interferon (IFN)-c [28]. Studies are being conducted on
the potential use of Salmonella typhimurium containing
vaccines in oncological therapy. Acute inflammatory con-
dition is considered a physiological process and a body’s
defensive response. Sometimes referred to as ‘‘therapeutic
inflammation’’ can show anticancer effects. However, it
should be remembered that pathogens try to avoid the
defense systems of the host, which may lead to a chronic
condition that often accompanies the neoplastic disease.
Chronic inflammatory condition: always bad
‘‘Pathological inflammation’’, i.e., acute phase response of
moderate intensity (chronic inflammation) is involved in
neoplastic transformation and stimulation of cancer growth
[29]. Already in 1828, Jean Nicholas Marjolin, a French
surgeon, provided evidence for the involvement of chronic
inflammation in the development of cancer. He observed
the growth of squamous cancer around the open chroni-
cally inflamed wound. It is currently estimated that
approximately 25 % of cancers are associated with chronic
inflammation caused by infection or physicochemical
agents [30]. Persistent gastritis induced by Helicobacter
pylori increases the risk of stomach cancer even by 75 %
[31], whereas types B and C hepatitis promote the forma-
tion of hepatocellular carcinoma [29]. Also noninfectious
diseases may increase the risk of cancer. Cancers of the
pancreas and prostate often follow chronic inflammation in
these organs [32]. The closest relationship between chronic
inflammation and cancer can be observed in chronic
ulcerating colitis and Crohn’s disease, which increase the
risk of colorectal cancer even tenfold [33]. Moreover,
inflammation-based tumors are characterized by the pres-
ence of cells and inflammatory mediators, thus indicating
that inflammation and cancer can be combined by the
extrinsic and intrinsic pathways. In the former, cancer
growth is associated with an ongoing inflammatory state.
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The latter is stimulated by genetic changes leading to the
activation of oncogenes and inactivation of suppressor
genes. Cells with an altered phenotype produce inflam-
matory mediators thus leading to the activation of immune
response and development of inflammation [34].
In both models, carcinogenesis is a two-stage process.
Cancer development is initiated when the DNA sequence
in somatic cells undergoes genetic mutations that can be
present in healthy tissues and remain occult for many years
until another stimulus pushes the cells into the ‘‘promo-
tion’’ stage [30]. This process may occur when the trans-
formed cells are exposed to chemical irritants, such as
phorbol esters, substances released at the site of injury,
partial resection of the organ, hormones or chronic irrita-
tion and inflammation. Functionally, many ‘‘promoters’’
may directly or indirectly induce cell proliferation,
recruitment of inflammatory cells, may increase production
of reactive oxygen species, leading to oxidative DNA
damage and decreasing its repair [35].
In the process of initiation normal cells undergo muta-
tion. Usually a single change in DNA is insufficient, but
4–5 mutations can direct cells onto the neoplastic trans-
formation pathway. Activated leukocytes release reactive
oxygen species (ROS) and reactive nitrogen intermediates
(RNI), which can induce DNA damage and genome
instability [8]. The major role of inflammation in mutage-
nesis can be exemplified by the development of colorectal
adenocarcinoma induced by inflammation and the action of
an irritant, dextran sodium sulfate (DSS) [35]. DSS itself
shows a weak carcinogenic effect, although the inflam-
matory state highly augments the effect [35]. Moreover, the
inflammatory cells producing cytokines may induce over-
expression of cytidine deaminase (activation-induced
cytidine deaminase-AID). AID causes genome instability
and increases the probability of mutations in the course of
abnormal binding of double stranded DNA, i.e., when most
frequently mutations form in oncogenesis-critical genes,
such as TP53, c-myc and Bcl-6. AID involvement has been
demonstrated in the formation of lymphomas, and gastric
and liver cancers [36]. Damage to DNA can also lead to the
inflammatory process and in consequence to cancer for-
mation. The examples include DEN-induced hepatocellular
carcinoma induced by DEN (diethylnitrosamine), which
causes DNA damage resulting in necrotic cell death and
inflammatory response that promotes cancer progression
[37]. Many oncoproteins (RAS, Myc, RET) can also acti-
vate the signaling pathways which enhance the production
of inflammatory cytokines and chemokines (IL-6, IL-8, IL-
1b, CCL2, CCL20) [34]. The initiation stage lasts until an
additional factor begins the stage of promotion, and thus
growth from single cells to a fully developed primary
cancer. The initial growth of cancer depends on the
increased cell proliferation and limited apoptosis, and these
two processes are stimulated by mechanisms closely rela-
ted to inflammation. In fact, most inflammatory mediators
that affect the growth of cancer act during the stage of
promotion. Moreover, inflammation-inducing factors are
also frequently cancer promoters [38]. The mechanisms
used by inflammatory condition to promote tumor growth
are numerous and extremely complex. Apart from
enhanced proliferation or increased survival they may also
involve the activation of angiogenesis and metastasizing.
This is associated, among others, with the production by
the transforming cancer cells of many cytokines and
chemokines which attract various populations of immune
cells, including macrophages, neutrophils, adipose cells,
dendritic cells and T, B and NK cells, which in turn infil-
trate tumor tissues and form tumor microenvironment [39].
Leukocytes may account for as many as 50 % of total
tumor mass. The interaction between cancer cells and
macrophages stimulates them to produce such cytokines as
IL-8, which stimulates further inflow of inflammatory cells.
In tumor microenvironment, cells communicate with one
another either by direct contact or production of various
mediators [40].
Concluding, inflammatory processes can modulate the
course of cancer, inhibiting or stimulating its growth. The
activity of inflammatory cells, and the type and level of the
inflammation-modulating factors affect the balance
between their pro- and antitumor effects. In the initial
phase of cancer growth, the acute phase responses may
show anticancer action, as it should be remembered that the
acute inflammatory reaction in itself is a physiological
reaction developing in response to a damaging stimulus
and aimed to eliminate the stimulus. It has been shown that
in certain types of cancers the ability to induce controlled
acute inflammatory condition is used as a therapy compo-
nent. However, in a chronic inflammatory state, especially
in tumor microenvironment, the presence of inflammatory
cells acts rather for the benefit of cancer cells, stimulating
their survival and proliferation.
The thorough knowledge and understanding of the
mechanisms that associate inflammation with neoplastic
disease may provide tangible benefits both in the scientific
and clinical aspects related to the introduction of new
diagnostic and therapeutic methods. The assessment of the
involvement of inflammation in respective neoplastic
lesions may affect the preventive and therapeutic measures
in patients with chronic inflammations.
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